NCT05065710已完成1 期
A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL- 1211 in Patients With Unresectable or Metastatic Solid Tumor
Zai Biopharmaceutical (Suzhou) Co., Ltd.21 个研究点 分布在 2 个国家目标入组 34 人开始时间: 2022年1月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 34
- 试验地点
- 21
- 主要终点
- Phase I ：MTD or MAD
研究概览
简要总结
This study is a Phase I/II, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of ZL-1211 administered by IV infusion on a every 2 weeks (Q2W) schedule.
详细描述
The study consists of two stages, Phase I -Dose Escalation Phase to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211, and Phase II -Cohort Expansion Phase to further define the safety and initial antitumor activity of ZL-1211 with the dose established in the Dose Escalation Phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are eligible to be included in the study only if all the following inclusion criteria apply:
- •Adults≥ 18 years of age.
- •Willing and able to provide signed and dated informed consent prior to any study related procedures and willing and able to comply with all study procedures.
- •All patients from Phase I and Phase II are required to provide tumor tissue for CLDN18.2 IHC assessment, and only patients with CLDN18.2-positive tumors will be included in this study.
- •Patients with histologically or cytologically confirmed metastatic or locally advanced solid tumors, refractory to standard treatment
- •Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Adequate hepatic function
- •Total bilirubin ≤ 1.5 × upper limit of normal (ULN).
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present.
- •Adequate renal function, as defined by serum creatinine < 1.5 × ULN OR calculated creatinine CL > 40 mL/min, Cockroft-Gault Equation:
- •Hematological function defined as:
- •Absolute neutrophil count ≥ 1.5 × 109/L without growth factor support in the 2 weeks prior to screening.
- •Platelet count ≥ 100 × 109/L without transfusion in the 2 weeks prior to screening.
- •Hemoglobin ≥ 9 g/dL without transfusion in the 2 weeks prior to screening.
- •Prothrombin time, international normalized ratio or/and activated partial thromboplastin time < 1.5 × ULN.
- •Recovery, to Grade 0-1, from AEs related to prior anticancer therapy except alopecia, < Grade 2 sensory neuropathy, lymphopenia.
排除标准
- •Patient with known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome related illness or known active or chronic hepatitis B virus infection or hepatitis C virus.
- •Any uncontrolled active infection.
- •Previous exposure to any CLDN18.2 antibody or CLDN18.2 chimeric antigen receptor T cell therapy.
- •Newly diagnosed or symptomatic brain metastases anticonvulsants are allowed.
- •Severe cardiovascular disease; New York Heart Association Class II-IV heart failure within 6 months of screening; uncontrolled arrhythmia within 6 months of screening.
- •Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to screening; palliative radiotherapy within 2 weeks prior to screening.
- •Major surgery within 4 weeks prior to first dose; minor surgery within 2 weeks prior to first dose.
- •Symptomatic intrinsic lung disease (chronic obstructive pulmonary disease, pulmonary fibrosis).
- •Gastrointestinal abnormalities including:
- •Documented unresolved gastric outlet obstruction or persistent vomiting defined as ≥ 3 episodes within 24 hours.
- •Active peptic ulcer disease required treatment in the past 3 months.
- •Gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.
- •Documented active colitis within 4 weeks prior to study entry, including infectious colitis, radiation colitis and ischemic colitis.
- •History of ulcerative colitis or Crohn's disease.
- •Patient has received systemic immunosuppressive therapy, including systemic corticosteroids 2 weeks prior to first dose of study drug.
研究组 & 干预措施
ZL-1211 monotherapy
Experimental
干预措施: ZL-1211 (Drug)
结局指标
主要结局
Phase I ：MTD or MAD
时间窗: One month
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211
Phase I and Phase II: safety and tolerability
时间窗: Approximately 10 months
Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Phase II: preliminary antitumor activity
时间窗: Approximately 10 months
Objective response rate defined as the proportion of patients with partial response (PR) proportion of patients with partial response (PR) or complete response (CR) based on Investigator assessment of tumor lesions per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
次要结局
- Phase I and Phase II: immunogenicity(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):Cmax(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):AUC(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):t1/2(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):Ctrough(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):Tmax(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):CL(Approximately 10 months)
- Phase II: preliminary antitumor activity(Approximately 10 months)
- Phase I and Phase II: pharmacokinetics (PK):Vss(Approximately 10 months)
研究者
研究点 (21)
Loading locations...
相似试验
已完成
1 期
First-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT04622774ImmunoGen, Inc.56
已完成
1 期
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid TumorsSolid Tumor, AdultOvarian Serous AdenocarcinomaBiliary Cancer MetastaticOvarian Serous CystadenocarcinomaPancreatic Ductal AdenocarcinomaNCT05074472ZielBio, Inc.35
终止
1 期
A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced TumoursAdvanced TumoursNCT04882176LaNova Medicines Limited18
撤回
1 期
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsUrothelial CarcinomaTriple Negative Breast CancerSquamous Cell Carcinoma of Head and NeckHormone Receptor-positive/HER2-negative Breast CancerNon-small Cell Lung CancerNCT05234606Silverback Therapeutics
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid TumorsMetastatic Solid TumorsNCT06031441Genentech, Inc.65